论文部分内容阅读
[目的]观察重组人红细胞生成素(rhEPO)对晚期乳腺癌化疗所致贫血的防治疗效。[方法]选择60例以多西紫杉醇为主的联合或单药化疗方案所致晚期乳腺癌贫血的患者(血红蛋白Hb≤110g/L,或化疗后Hb降低≥20g/L),随机分为两组,治疗组30例原方案化疗结束后48h皮下注射rhEPO 40000 IU/周,连用8周。对照组30例不给予rhEPO治疗,均服生血宁片2片/次,3次/d,连续8周。[结果]对照组随化疗周期贫血程度上升,而EPO治疗可以明显减少化疗所致的各项血液学指标下降程度(P<0.05)。8周内EPO治疗组完成化疗总周期数为78个周期,对照组为64个周期,化疗完成率分别为86.7%和73.6%,两组差异有统计学意义(P=0.003);EPO治疗组有3.3%(1/30)患者需要输血,对照组有27.6%(8/29)患者需要输血,两组之间差异有统计学意义(χ2=4.96,P=0.026)。[结论]EPO对以多西紫杉醇为主的联合或单药化疗方案所致晚期乳腺癌贫血有一定疗效,维持Hb水平,减少输血要求,为顺利完成化疗提供有力的保障。
[Objective] To observe the effect of recombinant human erythropoietin (rhEPO) in the prevention and treatment of anemia caused by chemotherapy in advanced breast cancer. [Methods] Sixty patients with anemia of advanced breast cancer (Hb≤110g / L or Hb≥20g / L after chemotherapy) were selected and divided into two groups at random, which were combined with docetaxel-based chemotherapy. Group, the treatment group, 30 cases of the original protocol 48h after the subcutaneous injection of rhEPO 40000 IU / week, once every 8 weeks. Control group, 30 patients were not given rhEPO treatment, were served Shengshening tablets 2 / times, 3 times / d, for 8 weeks. [Results] The control group increased with the degree of chemotherapy cycle anemia, EPO treatment can significantly reduce the degree of chemotherapy-induced hematological decline (P <0.05). In the 8 weeks, the total number of chemotherapy cycles in the EPO treatment group was 78 cycles and that in the control group was 64 cycles. The completion rates of chemotherapy were 86.7% and 73.6%, respectively, with significant difference between the two groups (P = 0.003) Blood transfusions were required in 3.3% (1/30) of the patients and in 27.6% (8/29) of the control patients. There was a significant difference between the two groups (χ2 = 4.96, P = 0.026). [Conclusion] EPO has a certain curative effect on the anemia of advanced breast cancer induced by combined docetaxel or monotherapy, maintaining the level of Hb, reducing the blood transfusion requirements and providing a powerful guarantee for the successful completion of chemotherapy.